肿瘤研究所公司 2025年季度报告

(562)735-3226Registrant's telephone number, including area code Securities registered pursuant to section 12(g) of the Act: NoneIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for suchshorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.YesýNo☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of Principal payments on long-term debt(20,000)Principal payments on financing leases(10)Common stock issued for options exercised137 Cash and cash equivalents at end of periodSupplemental disclosure of noncash investing and financing activities: Purchases of property and equipment included in accounts payableFinanced insurance premiums Supplemental disclosure of cash flow information:Cash paid for:$1,290$ 8 Overview of the BusinessThe Oncology Institute, Inc. (“TOI”),originally founded in 2007, is a leading, national platform delivering integrated direct care and cost management to patients and payors who are experiencingor managing members undergoing treatment for cancer and other complex medical conditions.Through wholly-owned subsidiaries and affiliated entities, TOI operates combined community clinics and infusion suites staffed with providers who administer latest-generation cancer treatmentsincluding chemotherapy, immunotherapy, oncolytics, and radiation oncology. Additionally, TOI provides coordinated case management, drug formulary management, and fully-delegated networks ofcare providers, all of which we use to drive improved treatment outcomes at the lowest possible cost to our patients and payors. Additionally, TOI operates a specialty pharmacy that includes both in- The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with Article 10 of Regulation S-X issued by the U.S. Securities andExchange Commission ("SEC"). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles ("GAAP") for complete consolidated financial statements. However, the Company believes that the disclosures are adequate to ensure the information is not misleading. In the opinion of management, all adjustments (of normaland recurring nature) considered necessary for fair presentation have been reflected in these interim statements. As such, the information included in the accompanying unaudited interim condensedconsolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes as of and for the year ended December31, 2024, issued on March26, 2025 in the Company's Annual Report on Form 10-K. The Company holds variable interests in TOI PCs, which it cannot legally own, as a result of entering into master services agreements ("MSAs"). As ofMarch31, 2025,TOI held variable interestsin TOI CA, The Oncology Institute FL, LLC, a Professional Corporation ("TOI FL"), The Oncology Institute OR, a Professional Corporation ("TOI OR"), and The Oncology Institute TX, a ProfessionalCorporation ("TOI TX"), all of which are VIEs. The Company is the primary beneficiary of the TOI PCs and thus, consolidates the TOI PCs in its financial statements. As discussed in Note 16, thenoncontrolling shareholders hold nominal interests in the VIEs and do not participate in the income or loss of the VIEs. the normal course of business. In connection with the preparation of the condensed consolidated financial statements for the three months ended March31, 2025, the Company conducted an evaluationas to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance ofsuch financial statements. The Company had cash and cash equivalents of $39,739and an accumulated deficit of $230,398at March31, 2025, and a net loss of $19,585and net cash used in operating of$4,988for the three months ended March31, 2025. On February 26, 2025, the Company entered into an Amendment to the Facility Agreement (see Note 11 - Debt) in which the Company made a partialprepayment of approximately $20,000together with accrued and unpaid interest. Among other items, the Amendment provided for the removal of the financial covenant that required the Company tohold at least $40,000of cash and cash equivalents. Additionally, on March 24, 2025, the Company entered into a securiti